Patients with Non-Insulin Depending Diabetes Mellitus and Metabolic Syndrome Are Suboptimal Treated in Swiss Primary Care

References

• Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003; 163:427–436.
   PubMed Web of Science ®Google Scholar
• Vinluan CM, Zreikat HH, Levy JR, Cheang KI. Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly. Metab: Clin Exp 2012; 61:302–309.
   PubMed Web of Science ®Google Scholar
• Landsberg L, Young JB. Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity. Int J Obes 1985; 9(Suppl 2):63–68.
   PubMedGoogle Scholar
• Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46:821–826.
   PubMed Web of Science ®Google Scholar
• Hypertension SSo. Arterielle Hypertonie, Empfehlungen für Ärzte, http://www.swisshypertension.ch/docs/guidelines_2009_d_leaflet.pdf. 2009, (Accessed January 2, 2013).
   Google Scholar
• Hochdruckliga D. Leitlinien zur Behandlung der arteriellen Hypertonie, 20. Auflage, http://www.hochdruckliga.de/ 2010, (Accessed January 2, 2013).
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Krone W, Hanefeld M, Meyer HF, Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2011; 25:186–195.
   PubMed Web of Science ®Google Scholar
• Brenner R, Waeber B, Allemann Y. Medical treatment of hypertension in Switzerland. The 2009 Swiss Hypertension Survey (SWISSHYPE). Swiss Medical Weekly 2011; 141:w13169.
   PubMedGoogle Scholar
• Schäfer HH, Sudano I, Theus GR, Zilla P, Noll G, Burnier M. Blood pressure target attainment in the background of guidelines: the very elderly in Swiss primary care. Fam Pract 2012; 29:511–520.
   PubMed Web of Science ®Google Scholar
• Agency CI. The World Factbook, https://www.cia.gov/library/publications/the-world-factbook/index.html. 2011, (Accessed January 2, 2013).
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Piche ME, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J, Lemieux S. The WHO and NCEP/ATPIII definitions of the metabolic syndrome in postmenopausal women: are they so different? Metab Syndr Relat Disord 2006; 4:17–27.
   PubMedGoogle Scholar
• Tanner RM, Brown TM, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep 2012; 14:152–159.
   PubMed Web of Science ®Google Scholar
• Babio N, Bulló M, Salas-Salvadó J. Mediterranean diet and metabolic syndrome: the evidence. Public Health Nutr 2009; 12(9A):1607–1617.
   PubMed Web of Science ®Google Scholar
• Hodge AM, English DR, Itsiopoulos C, O’Dea K, Giles GC. Does a Mediterranean diet reduce the mortality risk associated with diabetes: evidence from the Melbourne collaborative cohort study. Nutr Metab Cardiovasc Dis 2001; 21(9): 733–739.
   Google Scholar
• Chiva-Blanch G, Urpi-Sarda M, Ros E, Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin Nutr 2012 ; pii: S0261–5614(12)00189-6. doi: 10.1016/j.clnu.2012.08.022. [Epub ahead of print].
   Google Scholar
• Engeli S, Schling P, Gorzelniak K, The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35:807–825.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611–616.
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672–678.
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a North of Sweden efficacy evaluation (ALPINE study). J Hypertens 2003; 21:1563–1574.
   PubMed Web of Science ®Google Scholar
• van Vark LC, Bertrand M, Akkerhuis KM, Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33:2088–2097.
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253–259.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022–2031.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173–1181.
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219–224.
   PubMed Web of Science ®Google Scholar
• Harper R, Ennis CN, Heaney AP, A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38:853–859.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487–497.
   PubMed Web of Science ®Google Scholar
• Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens 1999; 13:477–483.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86:1182–1187.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5:295–309.
   PubMed Web of Science ®Google Scholar